BusinessWe invite you to partner up

In this pivotal imaging study we will validate the targeting ability of our lead Fibrobody® against PDGFRB, in patients suffering fibrosis. At the same time, the study will help us to identify those patients that would benefit most from Fibrobody-based therapy.  

Our lead FDC program focuses on creating Fibrobody® Conjugates based on our lead Fibrobody® against PDGFRB, that carry potent anti-fibrotic drugs to activated myofibroblasts in the liver.    

This exciting program explores the use Fibrobodies® as vectors for highly effective therapeutic siRNAs. These entities are notoriously ineffective in reaching the intended cells. Fibrobody®-siRNA Conjugates may take the best of both worlds.

This program focuses on creating Fibrobody® Conjugates that carry potent anti-fibrotic and anti-contractile drugs to activated myofibroblasts in pulmonary arterial hypertension, which is a severe and unmet medical need. 

We are developing novel Fibrobodies® against established and experimental targets to complement and benchmark our lead Fibrobody® against PDGFRB

This program explores the concept of using Fibrobodies® as vectors to carry potent cytytoxic drugs to activated myofibroblasts in fibrotic cancers, such as pancreatic adenocarcinoma.